肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor-based cell therapy for treating urological tumors.
泌尿系统肿瘤是全球重大的健康挑战，常规治疗往往不足以控制疾病进展。
泌尿系统肿瘤是重要的全球健康挑战，传统治疗往往不足以控制疾病进展。细胞免疫疗法近期取得突破，尤其是嵌合抗原受体（CAR）T细胞、CARNK 细胞和CAR巨噬细胞疗法，显示出治疗此类恶性肿瘤的显著潜力。当前研究正积极优化CAR策略，以提高对肿瘤相关抗原的靶向精度。本综述全面总结CAR细胞疗法在三种主要泌尿系统肿瘤中的应用：肾细胞癌、膀胱癌和前列腺癌。我们还分析这些方法目前的优势和局限，并提出以CAR-T细胞为重点的优化策略。本综述将展望该领域未来方向，并促进泌尿系统癌症患者更有效治疗方法的开发。
Urological tumors represent a significant global health challenge, with conventional therapies often proving insufficient to control disease progression. Recent breakthroughs in cellular immunotherapy, particularly in chimeric antigen receptor (CAR)-T cell, CAR-natural killer cell, and CAR-macrophage therapies, have demonstrated remarkable potential for treating these malignancies. Ongoing research is actively refining CAR-based strategies to enhance their precision in targeting tumor-associated antigens. This review comprehensively summarizes the applications of CAR cell therapy in the following 3 major urological tumors: renal cell carcinoma, bladder cancer, and prostate cancer. Furthermore, we analyzed the current advantages and limitations of these approaches and propose potential strategies for optimization focused on CAR-T cells. This review will provide future directions in this field and contribute to the development of more effective treatments for patients with urological cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
